Lucitanib Clinical Development Overview
Lucitanib, an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3).
Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. Clovis has received notice from Servier for termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us later in 2018. Clovis believes that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and is exploring a study of the combination. Clovis also intends to initiate a study of lucitanib in combination with rucaparib, based on encouraging data of VEGFR and PARP inhibitors in combination. Each of these studies is expected to initiate no later than the first quarter of 2019.